Cargando…

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

BACKGROUND: Ongoing efforts within the Alzheimer’s disease (AD) field have focused on improving the intra- and inter-laboratory variability for cerebrospinal fluid (CSF) biomarkers. Fully automated assays offer the possibility to eliminate sample manipulation steps and are expected to contribute to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leitão, Maria João, Silva-Spínola, Anuschka, Santana, Isabel, Olmedo, Veronica, Nadal, Alicia, Le Bastard, Nathalie, Baldeiras, Inês
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875031/ https://www.ncbi.nlm.nih.gov/pubmed/31759396 http://dx.doi.org/10.1186/s13195-019-0550-8

Ejemplares similares

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
por: Silva-Spínola, Anuschka, et al.
Publicado: (2022)

Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
por: Nojima, Hisashi, et al.
Publicado: (2022)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
por: Wilson, Edward N., et al.
Publicado: (2022)

Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans
por: Moon, Sohee, et al.
Publicado: (2021)

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment
por: Baldeiras, Inês, et al.
Publicado: (2018)

Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer’s disease
por: Marksteiner, Josef, et al.
Publicado: (2022)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer’s disease
por: Baldeiras, Inês, et al.
Publicado: (2019)

Clinical Utility and Cross-Reactivity of Insulin and C-Peptide Assays by the Lumipulse G1200 System
por: Oh, Jongwon, et al.
Publicado: (2018)

Analytical performance evaluation of Lumipulse® SARS‐CoV‐2 antigen assay in 392 asymptomatic patients
por: Petruzziello, Arnolfo, et al.
Publicado: (2023)

Reproducibility of Alzheimer’s Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions
por: Vogelgsang, Jonathan, et al.
Publicado: (2018)

Analytical evaluation of the novel Lumipulse G BRAHMS procalcitonin immunoassay
por: Ruzzenente, Orazio, et al.
Publicado: (2016)

Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases
por: Jesse, Sarah, et al.
Publicado: (2010)

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients
por: Zerr, Inga, et al.
Publicado: (2019)

The validation of macroprolactin analysis by polyethylene glycol precipitation using Fujirebio Lumipulse
por: Vermue, Febe C., et al.
Publicado: (2022)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
por: Llorens, Franc, et al.
Publicado: (2020)

Comparison of “Lumipulse anti‐Treponema pallidum” and “Architect Syphilis TP” and further examination
por: Liang, Jianbo, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
por: Czech, Christian, et al.
Publicado: (2012)

Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016)

Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods
por: Doecke, James D., et al.
Publicado: (2021)

Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest
por: Dakterzada, Farida, et al.
Publicado: (2021)

Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
por: Schmitz, Matthias, et al.
Publicado: (2022)

Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
por: Alexopoulos, Panagiotis, et al.
Publicado: (2016)

Low Diagnostic Yield of Routine Cerebrospinal Fluid Analysis in Juvenile Stroke
por: Prakapenia, Alexandra, et al.
Publicado: (2018)

Cerebrospinal fluid catecholamines in Alzheimer’s disease patients with and without biological disease
por: Henjum, Kristi, et al.
Publicado: (2022)

Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease
por: Silverberg, Gerald, et al.
Publicado: (2006)

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

A cerebrospinal fluid biosignature for the diagnosis of Alzheimer’s disease
por: Barichello, Tatiana, et al.
Publicado: (2019)

Putative autoantibodies in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lim, Bryant, et al.
Publicado: (2019)

Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer’s Disease
por: Do, Khanh V., et al.
Publicado: (2022)

Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis
por: Andrés-Benito, Pol, et al.
Publicado: (2020)

Lower CSF Amyloid-Beta(1–42) Predicts a Higher Mortality Rate in Frontotemporal Dementia
por: Vieira, Daniela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h0m3i4h0arehsm46mb9u0rfnrs